Contents

Highlights of This Issue 6367

SPECIAL FEATURES

CCR Translations

6369 Therapeutic Oligonucleotides: The Road Not Taken
Cy A. Stein and Sanjay Goel
See commentary p. 6582

Molecular Pathways

6373 The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression
Benjamin D. Hedley, Alison L. Allan, and Anargyros Xenocostas

6381 TLX1-Induced T-cell Acute Lymphoblastic Leukemia
Kim De Keersmaecker and Adolfo A. Ferrando

CCR Focus

6388 Antibody Conjugates: The Future Is Now
Susan E. Bates

6389 Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher and Ravi V.J. Chari

6398 Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman and Ira Pastan

6406 Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Martina Steiner and Dario Neri

6417 Antibody-Drug Conjugates of Calicheamicin Derivative: Gentiuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart

6428 Brentuximab Vedotin (SGN-35)
Jessica Katz, John E. Janik, and Anas Younes

6437 Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer
Patricia M. LoRusso, Denise Weiss, Ellie Guardino, Sandhya Girish, and Mark X. Slawkowski

6448 SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carez, Robert J. Lutz, and John M. Lambert

6459 Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC
René H. Medema, Chia-Chi Lin, and James Chih-Hsin Yang

6467 Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism
Christopher G. Twitty, Shawn M. Jensen, Hong-Ming Fu, and Bernard A. Fox

6482 Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Ning Jin, Tianyun Jiang, David M. Rosen, Barry D. Nelkin, and Douglas W. Ball

6490 The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6500</td>
<td>Significant Biological Role of Sp1 Transactivation in Multiple Myeloma</td>
<td>Mariateresa Fulciniti, Samir Amin, Puru Nanjappa, Scott Rodig, Rao Prabhala, Cheng Li, Stephane Minvielle, Yu-tzu Tai, Pierfrancesco Tassone, Herve Avet-Loiseau, Teru Hideshima, Kenneth C. Anderson, and Nikhil C. Munshi</td>
</tr>
<tr>
<td>6522</td>
<td>EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies</td>
<td>Virginie Poindessous, Djamila Ouaret, Karima El Ouadrani, Aude Battistella, Virginie F. Boulodou, Sylvie Dumont, Pascale Cervera, Jean-François Fédou, Thierry André, Christophe Tourjany, Bénoist Chibaudel, Aimery de Gramont, and Annette K. Larsen</td>
</tr>
<tr>
<td>6531</td>
<td>Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers</td>
<td>Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Federica Di Nicolantonio, Aldo Scarpa, Alberto Bardelli, and Giampaolo Tortora</td>
</tr>
<tr>
<td>6553</td>
<td>Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma</td>
<td>Mirwais Wardak, Christiaan Schippers, Magnus Dahlbom, Timothy Cloughesy, Wei Chen, Najicetettai Satyamurthy, Johannes Czermin, Michael E. Phelps, and Sung-Cheng Huang</td>
</tr>
<tr>
<td>6563</td>
<td>PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients</td>
<td>Tamara L. Lotan, Bora Gurel, Siobhan Sutcliffe, David Esopi, Wernman Liu, Junfeng Xu, Jessica L. Hicks, Ben H. Park, Elizabeth Humphreys, Alan W. Partin, Misop Han, George J. Netto, William B. Isaacs, and Angelo M. De Marzo</td>
</tr>
<tr>
<td>6574</td>
<td>Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin</td>
<td>Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Christensen, Christopher Ruel, Janice Shippe-Spotloe, David R. Gandara, Alice Chen, and John M. Kirkwood</td>
</tr>
<tr>
<td>6592</td>
<td>Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials</td>
<td>Ming-Wen An, Sumithra J. Mandrekar, Megan E. Branda, Shauna L. Hillman, Alex A. Adjei, Henry C. Pitot, Richard M. Goldberg, and Daniel J. Sargent</td>
</tr>
</tbody>
</table>
LETTERS TO THE EDITOR

KRAS rs61764370 in Epithelial Ovarian Cancer—Letter
Joanne B. Weidhaas and Frank J. Slack

KRAS rs61764370 in Epithelial Ovarian Cancer—Response
Harvey A. Risch, Andrew Berchuck, and Paul D.P. Pharoah; for the Ovarian Cancer Association Consortium

ABOUT THE COVER

The work by Poindessous and colleagues shows that inhibition of EGFR- and VEGF(R)-signaling by combinations of two small molecule tyrosine kinase inhibitors (TKI), afatinib and vandetanib, has synergistic activity in colorectal cancer models that are refractory to combinations of the monoclonal antibodies cetuximab and bevacizumab. Importantly, only the TKIs were able to attenuate the phosphorylation of intracellular EGFR- and VEGFR-receptors which was accompanied by the induction of apoptotic cell death as indicated by TUNEL staining (nuclear DNA in blue, apoptotic nuclei in white). This work provides a rationale for clinical trials of the afatinib and vandetanib combination, even in patients with mutant KRAS. For details, see the article by Poindessous and colleagues on page 6522 of this issue.